BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 22626690)

  • 1. The next generation of therapies for adrenocortical cancers.
    Kirschner LS
    Trends Endocrinol Metab; 2012 Jul; 23(7):343-50. PubMed ID: 22626690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant mitotane in adrenocortical carcinoma.
    Dickstein G; Shechner C; Nativ O
    N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant mitotane therapy of adrenal cancer - use and controversy.
    Schteingart DE
    N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant mitotane in adrenocortical carcinoma.
    Bertherat J; Coste J; Bertagna X
    N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant mitotane in adrenocortical carcinoma.
    Lee JE
    N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
    [No Abstract]   [Full Text] [Related]  

  • 6. Xenograft models for preclinical drug testing: implications for adrenocortical cancer.
    Luconi M; Mannelli M
    Mol Cell Endocrinol; 2012 Mar; 351(1):71-7. PubMed ID: 22056412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Practical use of o,p'DDD in adrenocortical carcinoma].
    Bacchetta J; Droz JP
    Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mitotane in the treatment of adrenal carcinoma].
    Sane T
    Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
    Lecka A; Ginalska-Malinowska M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update in adrenocortical carcinoma.
    Fassnacht M; Kroiss M; Allolio B
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary management of adrenocortical carcinoma.
    Zini L; Porpiglia F; Fassnacht M
    Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
    Berruti A; Fassnacht M; Baudin E; Hammer G; Haak H; Leboulleux S; Skogseid B; Allolio B; Terzolo M
    J Clin Oncol; 2010 Aug; 28(23):e401-2; author reply e403. PubMed ID: 20567001
    [No Abstract]   [Full Text] [Related]  

  • 13. Mitotane treatment for adrenocortical carcinoma: an overview.
    De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
    Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
    Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
    Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
    Demeure MJ; Somberg LB
    Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for adrenocortical carcinoma.
    Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
    Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
    Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure.
    Kojori F; Cronin CM; Salamon E; Burym C; Sellers EA
    J Pediatr Endocrinol Metab; 2011; 24(3-4):203-4. PubMed ID: 21648293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant mitotane in adrenocortical carcinoma.
    Machens A; Dralle H
    N Engl J Med; 2007 Sep; 357(12):1258-9; author reply 1259. PubMed ID: 17891837
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.